Prostate Cancer International is
for 2011 by Great NonProfits
A newly published Italian study offers what we believe to be the first direct comparison of two “modern” types of external beam radiation therapy for the treatment of localized, high-risk prostate cancer. This is a relatively small trial, with relatively brief follow-up to date, but the results are nontheless interesting and important.
Filed under: Management, Treatment | Tagged: "high risk", external beam radiation, localized, randomized, trial | 2 Comments »
It is clear from a report in the December issue of Urologic Oncology that the neoadjuvant use of chemohormonal therapy prior to surgery or radiation is not going to be a “cure-all” for prostate cancer patients initially diagnosed with high-risk, locally advanced prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", chemotherapy, locally advanced, neoadjuvant | Leave a Comment »
Today’s news reports summarize papers recently published on: Optimism, pessimism, and long-term health outcomes External beam radiation + hormone therapy for high-risk patients Quality of life and health utility after radical prostatectomy Paclitaxel + estradiol combination therapy in men progressing after docetaxel-based chemotherapy
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", estradiol, hormone therapy, HRQOL, optimism, outcomes, paclitaxel, pessimism, quality of life, radiation, radical prostatectomy | Leave a Comment »
Earlier this week we published reports on work from Memorial Sloan-Kettering Cancer Center and Johns Hopkins regarding the role of surgery as first-line treatment for men with high-risk prostate cancer. The topic appears to be coming into fashion.
Filed under: Management, Treatment | Tagged: "high risk", first line, surgery | Leave a Comment »
A number of trials are currently evaluating the potential value of adjuvant chemotherapy after first-line treatment in men with high-risk prostate cancer. The effects of this form of treatment on long-term outcomes still to be established, but …
Filed under: Management, Treatment | Tagged: "high risk", adjuvant, chemotherapy, paclitaxel | Leave a Comment »
As a follow-up to yesterday’s report on Scardino’s presentation to the New York section of the AUA, it is worth noting a publication last November from Johns Hopkins. The research group’s goal was to investigate long-term survival following radical prostatectomy as first-line treatment in their patients with high-risk prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", outcomes, radical prostatectomy, surgery | 6 Comments »
Earlier today we reported data from a series of patients treated by Stock et al. with brachytherapy + external beam radiation therapy (EBRT) + androgen deprivation therapy (ADT). According to a HealthDay report published in Forbes magazine, a second paper appears to endorse the findings of Stock and his colleagues.
Filed under: Management, Risk, Treatment, Uncategorized | Tagged: "high risk", ADT, androgen deprivation therapy, brachytherapy, EBRT, external brea, outcomes, radiation therapy | 1 Comment »
Some years have passed since D’Amico and colleagues developed their risk classification system for newly diagnosed prostate cancer patients which placed any patient with a PSA > 20 ng/ml into the high-risk category. And since the introduction of that classification system, we are aware of limited data on the long-term outcomes of surgical treatment of [...]
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: "high risk", patients, surgery | Leave a Comment »
An Italian study has reported data from a retrospective analysis of outcomes after radical surgery and external beam radiation therapy (EBRT) + androgen deprivation therapy (ADT) in first-line treatment of two, pre-treatment-defined, concurrently treated, high-risk patient populations, all treated at a single institution between January 2003 and December 2007.
Filed under: Management, Treatment | Tagged: "high risk", comparison, radiation, surgery | 2 Comments »
Two papers presented at the meeting on Monday this week addressed radical prostatectomy in high risk patients and different applications of androgen deprivation therapy for their impact on overall patient survival, using the Johns Hopkins patient database as their starting point.
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen deprivation therapy, radical prostatectomy, survial | Leave a Comment »
The concurrence of the Passover and Easter holidays this year appears to have limited medical science reports this weekend. There are really only two reports worth mentioning, and even they are of limited interest.
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", adjuvant therapy, immunotherapy, post-prostatectomy, vaccines | Leave a Comment »
A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity.
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", Abraxane, locally advanced, neoadjuvant, paclitaxel | Leave a Comment »
A series of recent reviews, in the current issue of the Canadian Journal of Urology and elsewhere, have addressed some of the more topical issues in the diagnosis and management of prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", ADT, HDR brachytherapy, PSA | Leave a Comment »
A wide variety of clincal and pathological criteria have been proposed as data sets to stratify men into “high risk” prostate cancer groups. Nguyen et al. have now published data suggesting that the stratification criteria actually have no effect on survival (at least for six of the more commonly used criteria sets).
Filed under: Management, Treatment | Tagged: "high risk", outcome, prostatectomy | Leave a Comment »
We have separately commented on a Swedish pilot study showing that men treated with captopril following radical prostatectomy had a significant reduction in risk of biochemical recurrence. Other reports today deal with: The potential of contrast enhanced eMRI in diagnosis and monitoring Whether we can better identify high-risk patients with localized disease for curative surgery Early-stage [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", contrast-enhanced eMRI, depression, hot flashes, mortality, surgery | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site